Epie Boven
Epie Boven
Hoogleraar Medische Oncologie, VUmc, Amsterdam
Geverifieerd e-mailadres voor vumc.nl
Geciteerd door
Geciteerd door
Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess
T Lindmo, E Boven, F Cuttitta, J Fedorko, PA Bunn Jr
Journal of immunological methods 72 (1), 77-89, 1984
Effect of low-intensity physical activity and moderate-to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy …
H Van Waart, MM Stuiver, WH van Harten, E Geleijn, JM Kieffer, ...
Journal of clinical oncology 33 (17), 1918-1927, 2015
Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer
MB de Ruiter, L Reneman, W Boogerd, DJ Veltman, FSAM Van Dam, ...
Human brain mapping 32 (8), 1206-1219, 2011
Late effects of high‐dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging
MB de Ruiter, L Reneman, W Boogerd, DJ Veltman, M Caan, G Douaud, ...
Human brain mapping 33 (12), 2971-2983, 2012
Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized …
SFA Duijts, M van Beurden, HSA Oldenburg, MS Hunter, JM Kieffer, ...
Journal of Clinical Oncology 30 (33), 4124-4133, 2012
Pretreatment Deoxycytidine Kinase Levels Predict in Vivo Gemcitabine Sensitivity
JR Kroep, WJP Loves, CL Van Der Wilt, E Alvarez, I Talianidis, E Boven, ...
Molecular cancer therapeutics 1 (6), 371-376, 2002
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity
NP van Erp, K Eechoute, AA van der Veldt, JB Haanen, AKL Reyners, ...
Journal of Clinical Oncology 27 (26), 4406-4412, 2009
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
K Mross, P Maessen, WJ Van Der Vijgh, H Gall, E Boven, HM Pinedo
Journal of Clinical Oncology 6 (3), 517-526, 1988
Breast cancer classification by proteomic technologies: current state of knowledge
SW Lam, CR Jimenez, E Boven
Cancer treatment reviews 40 (1), 129-138, 2014
Sunitinib for treatment of advanced renal cell cancer: primary tumor response
AAM Van der Veldt, MR Meijerink, AJM van den Eertwegh, A Bex, ...
Clinical Cancer Research 14 (8), 2431-2436, 2008
Beta-glucuronidase-mediated drug release
M Graaf, E Boven, HW Scheeren, HJ Haisma, HM Pinedo
Current pharmaceutical design 8 (15), 1391-1403, 2002
Development and molecular characterization of a 2′, 2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780
VWTR Van Haperen, G Veerman, S Eriksson, E Boven, APA Stegmann, ...
Cancer research 54 (15), 4138-4143, 1994
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
AAM van der Veldt, MR Meijerink, AJM van den Eertwegh, JBAG Haanen, ...
British journal of cancer 102 (5), 803-809, 2010
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival
H van Cruijsen, AAM van der Veldt, L Vroling, D Oosterhoff, ...
Clinical Cancer Research 14 (18), 5884-5892, 2008
Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method
RWF Van Leeuwen, EL Swart, E Boven, FA Boom, MG Schuitenmaker, ...
Annals of oncology 22 (10), 2334-2341, 2011
CPT‐11 in human colon‐cancer cell lines and xenografts: characterization of cellular sensitivity determinants
WJM Jansen, B Zwart, STM Hulscher, G Giaccone, HM Pinedo, E Boven
International journal of cancer 70 (3), 335-340, 1997
Schedule dependence of sensitivity to 2′, 2′-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and …
VWTR Van Haperen, G Veerman, E Boven, P Noordhuis, JB Vermorken, ...
Biochemical pharmacology 48 (7), 1327-1339, 1994
Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1α protein by the oxidative stressor arsenite
MCA Duyndam, TM Hulscher, D Fontijn, HM Pinedo, E Boven
Journal of Biological Chemistry 276 (51), 48066-48076, 2001
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models
HR Hendriks, PE Pizao, DP Berger, KL Kooistra, MC Bibby, E Boven, ...
European Journal of Cancer 29 (6), 897-906, 1993
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
AAM van der Veldt, E Boven, HH Helgason, M van Wouwe, J Berkhof, ...
British journal of cancer 99 (2), 259-265, 2008
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20